Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Rapid Micro Biosystems Announced 5-Year Distribution Deal With Merck KGaA's Life Science Unit; MilliporeSigma Gains Co-Exclusive Rights To Sell Growth Direct Systems; Collaboration To Cut Costs And Expand Margins; Additional Joint Development Opportunities Explored

Author: Benzinga Newsdesk | February 27, 2025 05:56pm

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year global distribution and collaboration agreement (the "Agreement") with the Life Science business of Merck KGaA , Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma").

The agreement grants MilliporeSigma global co-exclusive rights to sell Growth Direct systems and related consumables. MilliporeSigma may sell to customers in the pharmaceutical, medical device, personal care, cosmetics and food and beverage fields worldwide. Rapid Micro will continue to utilize its existing direct sales team and distribution channels to sell, place, validate and service its products globally. Rapid Micro will also maintain responsibility to install, validate and service any Growth Direct system sold by MilliporeSigma.

The initial term of the agreement is five years and includes a commitment to purchase a minimum number of Growth Direct systems during each of the first two years.

The agreement also enables collaboration with respect to the Company's product and supply chain costs. In this regard, the parties intend to explore cost savings focused on leveraging MilliporeSigma's product offerings, manufacturing capabilities and scale to accelerate progress on the Company's strategic priority of expanding gross margins.

The agreement also enables the parties to explore additional collaboration opportunities, including services and joint technology development efforts to enhance existing offerings and introduce new products.

Posted In: RPID

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist